Celgene data paves way for longer term use of Revlimid, says Bernstein Bernstein believes that positive data for Celgene's Revlimid in multiple myeloma should increase the amount of time for which the drug is used in the U.S. and EU markets. The firm thinks that the data should enable the company's revenue in Europe to double in 3-5 years. It keeps an Outperform rating on the stock.
News For CELG From The Last 14 Days
Check below for free stories on CELG the last two weeks.